Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumorigenesis driven by the BRAFV600E oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion.
Gadal S, Boyer JA, Roy SF, Outmezguine NA, Sharma M, Li H, Fan N, Chan E, Romin Y, Barlas A, Chang Q, Pancholi P, Timaul NM, Overholtzer M, Yaeger R, Manova-Todorova K, de Stanchina E, Bosenberg M, Rosen N. Gadal S, et al. Among authors: rosen n. bioRxiv [Preprint]. 2024 Apr 20:2023.11.21.568071. doi: 10.1101/2023.11.21.568071. bioRxiv. 2024. PMID: 38659913 Free PMC article. Preprint.
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Among authors: rosen n. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N. Yaeger R, et al. Among authors: rosen n. Cancer Res. 2017 Dec 1;77(23):6513-6523. doi: 10.1158/0008-5472.CAN-17-0768. Epub 2017 Sep 26. Cancer Res. 2017. PMID: 28951457 Free PMC article.
RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N. Yao Z, et al. Among authors: rosen n. Nat Med. 2019 Feb;25(2):284-291. doi: 10.1038/s41591-018-0274-5. Epub 2018 Dec 17. Nat Med. 2019. PMID: 30559419 Free PMC article.
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H. Yaeger R, et al. Among authors: rosen n. Clin Cancer Res. 2019 Dec 1;25(23):7089-7097. doi: 10.1158/1078-0432.CCR-19-2004. Epub 2019 Sep 12. Clin Cancer Res. 2019. PMID: 31515458 Free PMC article. Clinical Trial.
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, Bowles DW, Gadgeel SM, Mihalcioiu C, Papadopoulos KP, Diamond EL, Sturtz KB, Feng G, Drescher SK, Reddy MB, Sengupta B, Maity AK, Brown SA, Singh A, Brown EN, Baer BR, Wong J, Mou TC, Wu WI, Kahn DR, Gadal S, Rosen N, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM. Yaeger R, et al. Among authors: rosen n. Cancer Discov. 2024 Sep 4;14(9):1599-1611. doi: 10.1158/2159-8290.CD-24-0024. Cancer Discov. 2024. PMID: 38691346 Free PMC article. Clinical Trial.
Diet induced insulin resistance is due to induction of PTEN expression.
Rosen N, Mukherjee R, Pancholi P, Sharma M, Solomon H, Timaul M, Thant C, McGriskin R, Hayatt O, Markov V, D'Allara J, Bekker S, Candelier J, Carrasco S, de Stanchina E, Vanaja K. Rosen N, et al. Res Sq [Preprint]. 2024 Jun 27:rs.3.rs-4021885. doi: 10.21203/rs.3.rs-4021885/v1. Res Sq. 2024. PMID: 38978604 Free PMC article. Preprint.
Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer.
Kitai H, Choi PH, Yang YC, Boyer JA, Whaley A, Pancholi P, Thant C, Reiter J, Chen K, Markov V, Taniguchi H, Yamaguchi R, Ebi H, Evans J, Jiang J, Lee B, Wildes D, de Stanchina E, Smith JAM, Singh M, Rosen N. Kitai H, et al. Among authors: rosen n. Nat Commun. 2024 Jul 19;15(1):6076. doi: 10.1038/s41467-024-50063-z. Nat Commun. 2024. PMID: 39025835 Free PMC article.
743 results